深圳粒影生物科技有限公司重組三螺旋結構膠原蛋白已正式被納入國際化妝品原料（INCI）目錄（INCI編號40302），這是膠原蛋白首次被INCI列為三聚體，也是首個被收錄的重組三螺旋膠原蛋白，并將“三螺旋”直接接受為有結構的膠原蛋白商品名，這標志著粒影生物三螺旋重組膠原蛋白正式走向國際市場。
Shenzhen LiYing Biotechnology Co., Ltd.'s recombinant triple-helix collagen has been officially included in the International Nomenclature of Cosmetic Ingredients (INCI) directory (INCI No. 40302). This marks the first time collagen has been listed by INCI as a trimer, with the "Tri-helix" directly recognized as structured collagen. It signifies that LIYING BIO's recombinant triple-helix collagen is now officially entering the international market.
圖一：INCI分配信
Figure 1. INCI Assignment Letter
INCI名稱是國際公認用于識別化妝品成分的系統名稱，由國際命名委員會(International Nomenclature Committee，簡稱為INC)審核和分配，并由美國個人護理產品協會(Personal Care Products Council，簡稱為PCPC)發布在《國際化妝品成分字典和手冊》中。這些名稱在全球范圍內被認可，用于識別化妝品成分，旨在確保化妝品成分的準確性和一致性。
The INCI name is an internationally recognized system for identifying cosmetic ingredients. They are reviewed and assigned by the International Nomenclature Committee (INC), and published by the Personal Care Products Council (PCPC) in the International Cosmetic Ingredient Dictionary and Handbook. These names are globally accepted for identifying cosmetic ingredients, ensuring accuracy and consistency in cosmetic formulations.
粒影生物的三螺旋膠原蛋白結構穩定、功效強，生物相容性好，具有顯著的抗衰、修復、抗皺和美白功效，不僅能應用在護膚和日化領域，還能夠應用于臨床醫學，如醫美填充、創面修復及骨科等領域。此外，其耐高溫特性使其能夠適應多種生產與應用環境。
LIYING BIO's Tri-helix collagen features a stable structure, high efficacy, and excellent biocompatibility, delivering remarkable anti-ageing, reparative, anti-wrinkle, and brightening benefits. Beyond skincare and personal care applications, it is also suitable for clinical medical uses, such as aesthetic fillers, wound repair, and orthopaedic treatments. Additionally, its heat-resistant properties enable versatile adaptation to diverse production and application environments.
圖二：結構與功能驗證
Figure 2. Structural and Functional Verification
圖三：毒理檢測報告
Figure 3. Toxicology Test Report
粒影生物通過生物合成的方法，結合人工智能計算、設計、改造獲得高活性蛋白質，構建高適配工程菌株，實現了具有三螺旋結構的重組人源化膠原蛋白的成功表達和高效生產，并形成以ZL 202410624084.X等十余項核心專利、二十多項外圍專利的技術包，同時布局海外專利，筑起專利墻。憑借這些創新成果，粒影生物獲得了多項榮譽與資質。
LIYING BIO employs synthetic-biology approaches, integrating AI-powered computation, design, and modification to develop highly active proteins. The company has successfully constructed high-efficiency engineered bacterial strains capable of expressing and producing recombinant humanized collagen with a stable Tri-helix structure. Backed by a robust IP portfolio - including core patents such as ZL 202410624084.X (with over 10 core patents and 20+ peripheral patents) and strategic international patent filings - LIYING BIO has established a comprehensive patent protection system. These technological breakthroughs have earned the company numerous prestigious awards and certifications in recognition of its innovations.
圖四：自主發明專利
Figure 4: Independent Invention Patents
圖五：獲獎情況
Figure 5: Awards
圖六：獎勵證書
Figure 6: Award Certificate
目前，粒影生物的三螺旋膠原蛋白已經成功應用于市場，并在多個領域展現出巨大的應用潛力，自主研發的護膚品牌Tri-helix于2024年底正式上線，并受到消費者一致好評。
Currently, LIYING BIO 's Tri-helix collagen has been successfully commercialized and demonstrates significant potential across multiple applications. The company's proprietary skincare brand, Tri-helix, officially launched in late 2024 and has received unanimous acclaim from consumers.
圖七：顧客反饋
Figure 7：customer feedback
